ASX:RCE Recce Pharmaceuticals (RCE) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Recce Pharmaceuticals Stock (ASX:RCE) 30 days 90 days 365 days Advanced Chart Remove Ads Get Recce Pharmaceuticals alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume630,087 shsAverage VolumeN/AMarket Capitalization$104.34 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewRecce Pharmaceuticals Ltd, a biotechnology company, discovers, develops, and commercializes synthetic antiinfectives in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer antibiotic formulated for oral use. In addition, the company engages in R327 Intravenous which provides serious/life-threatening bacterial infections, including sepsis which is in the phase 1 trial; urinary tract infections, including urosepsis; rapid infusions sepsis in the phase 2 trial; and R327 Topical offers wound infections, including infected burns; and diabetic foot ulcer infections in Phase 2 trails. Further, the company operates various pre-clinical programs, such as Mycobacterium abscessus which is in phase 1 clinical trial; bacterial sinusitis; and additional TBA. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.Read More… Remove Ads Receive RCE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Recce Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address RCE Stock News HeadlinesRecce Pharmaceuticals Unveils Strategic Focus on Synthetic Anti-InfectivesMarch 19, 2025 | tipranks.comBiocurious: For Recce, our near neighbour was the obvious place to launch a diabetes-related trialMarch 11, 2025 | msn.comTrump… a socialist? Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 2, 2025 | Porter & Company (Ad)Recce Pharmaceuticals Granted Japanese Patent for RECCE® Anti-InfectivesFebruary 27, 2025 | markets.businessinsider.comRecce Pharmaceuticals secures Japanese patent in world’s third-largest pharmaceutical marketFebruary 26, 2025 | au.investing.comRecce Pharmaceuticals Secures Japan Patent for Anti-InfectivesFebruary 25, 2025 | tipranks.comRecce Pharmaceuticals receives positive Phase II results for R327G in bacterial skin infectionsFebruary 17, 2025 | au.investing.comRecce soars on phase II skin infection trial resultsFebruary 17, 2025 | msn.comSee More Headlines RCE Stock Analysis - Frequently Asked Questions How were Recce Pharmaceuticals' earnings last quarter? Recce Pharmaceuticals Ltd (ASX:RCE) posted its earnings results on Wednesday, February, 27th. The company reported ($0.01) earnings per share for the quarter. Recce Pharmaceuticals had a positive trailing twelve-month return on equity of 392.94% and a negative net margin of 741.65%. What other stocks do shareholders of Recce Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Recce Pharmaceuticals investors own include ASE Technology (ASX), FlexiGroup Limited (FXL.AX) (FXL), Immutep (IMMP), Mavenir (MVNR), Cronos Group (CRON), Cree (CREE) and Caladrius Biosciences (CLBS). Company Calendar Last Earnings2/27/2019Today4/02/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:RCE CIKN/A Webwww.recce.com.au Phone61 2 8075 4585FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17,660,000.00 Net Margins-741.65% Pretax MarginN/A Return on Equity392.94% Return on Assets-238.11% Debt Debt-to-Equity Ratio-8.52 Current Ratio0.34 Quick Ratio4.81 Sales & Book Value Annual Sales$5.03 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow13.57 Book ValueA($0.05) per share Price / BookN/AMiscellaneous Outstanding Shares231,870,000Free FloatN/AMarket Cap$104.34 million OptionableNot Optionable Beta1.05 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (ASX:RCE) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recce Pharmaceuticals Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Recce Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.